Every 424B that Theriva Biologics, Inc. (TOVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOVX filings page.
Theriva Biologics, Inc. is registering 16,184,560 shares of common stock for resale by existing investors, covering shares issuable upon exercise of “New Warrants” issued in an October 2025 warrant inducement transaction. Those investors had previously held warrants to buy 8,092,280 shares, which they agreed to exercise for cash at a reduced price of $0.54 per share. In return, Theriva issued New Warrants for 16,184,560 additional shares, also at $0.54 per share.
Theriva has already received approximately $4.4 million in gross proceeds from the exercised prior warrants, before fees. The company will not receive any proceeds from resale of the registered shares, but would receive cash only if holders exercise the New Warrants. Shares outstanding were 33,739,643 as of November 3, 2025, and would be 49,924,203 assuming full exercise of the New Warrants. The stock last closed at $0.2189 per share on the NYSE American under the symbol “TOVX.”
Theriva Biologics (TOVX) filed a prospectus supplement for an at‑the‑market program to sell up to $2,894,225 of common stock under its Amended and Restated Sales Agreement with A.G.P./Alliance Global Partners.
Sales may occur on the NYSE American as defined in Rule 415, with the Sales Agent earning a commission of up to 3.0% of the gross sales price; there is no escrow arrangement. The company plans to use any net proceeds for working capital and general corporate purposes, including research and development and manufacturing scale‑up, and may also invest in or acquire products, businesses, or technologies.
The company cites a public float of approximately $28,332,900 (based on 33,729,643 non‑affiliate shares at $0.84 as of October 15, 2025), and notes it may not sell more than one‑third of its public float on Form S‑3 in any 12‑month period while float remains below $75 million. The last reported sale price was $0.3276 per share on October 27, 2025.
Theriva Biologics (TOVX) launched an at‑the‑market (ATM) offering of up to $4,019,597 of common stock under a prospectus supplement to its effective S‑3 shelf. Sales will be made through A.G.P./Alliance Global Partners as sales agent, which will earn a commission of up to 3.0% of the gross sales price per share.
The filing is made pursuant to General Instruction I.B.6 to Form S‑3, which limits primary sales to one‑third of public float; the company reports a public float of approximately $19,659,047 based on 23,403,628 non‑affiliate shares at $0.84 as of October 15, 2025. The company notes it sold approximately 12,016,073 shares for net proceeds of about $6.1 million through the Sales Agreement during the period ended December 31, 2024 through the date of the supplement.
For illustration, the company shows up to 13,407,595 shares at an offering price of $0.2998 (the October 21, 2025 last sale price), with actual shares varying by market price. Intended uses include working capital and general corporate purposes, including research and development and manufacturing scale‑up.
Theriva Biologics (TOVX) amended certain existing warrants, reducing the exercise price from $2.00 to $0.54 per share for warrants held by certain holders covering up to 1,345,000 shares of common stock. The change was executed on October 16, 2025 and disclosed via this amendment to a prior prospectus supplement tied to the company’s effective S-1.
The filing updates the earlier prospectus to reflect the revised pricing terms for these “Existing Warrants.” This adjustment affects only the warrant exercise price mechanics and does not alter the previously described securities from the earlier offering materials. Theriva’s common stock closed at $0.84 on October 15, 2025 on the NYSE Capital Market, providing context for the new exercise price.
Theriva Biologics (TOVX) amended certain outstanding warrants, lowering the exercise price from $1.10 to $0.54 per share for warrants to purchase up to 6,747,280 shares of common stock. The change was agreed with the relevant warrant holders on October 16, 2025, and updates the prior prospectus supplement disclosure.
The company’s common stock trades on the NYSE Capital Market under “TOVX.” On October 15, 2025, shares closed at $0.84. This amendment pertains to previously issued warrants tied to a prior best efforts offering; it does not describe a new sale of shares.
Theriva Biologics filed a prospectus supplement disclosing an amendment to certain existing warrants. On October 16, 2025, the company reduced the exercise price on warrants to purchase up to 1,385,000 shares of common stock from $2.00 to $0.54 per share.
This supplement updates the company’s previously effective S-1 prospectus. The change applies only to specified “Existing Warrants” held by certain holders. Theriva’s common stock trades on the NYSE Capital Market under the symbol TOVX, and the closing price was $0.84 per share on October 15, 2025.
Theriva Biologics (TOVX) filed a prospectus supplement to disclose an amendment to certain outstanding common warrants. On October 16, 2025, the company and certain holders agreed to reduce the exercise price on Existing Warrants covering up to 6,727,280 shares of common stock from $1.10 to $0.54 per share. The supplement updates the previously effective S-1 prospectus tied to the May 2025 best efforts offering. Theriva’s common stock closed at $0.84 on October 15, 2025 on the NYSE Capital Market under the symbol TOVX.